The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM.
Expert Opin Drug Saf · review; journal article · DOI 10.1517/14740338.2016.1135899 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för rolapitant. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
12 hitsState of the Art Antiemetic Therapy for Cancer Patients.
Lau TK, Yip CH, Yeo W.
Curr Oncol Rep · review; journal article · DOI 10.1007/s11912-015-0486-5Rolapitant: first global approval.
Syed YY.
Drugs · review; journal article · DOI 10.1007/s40265-015-0485-8Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C, Slusher BS.
Cancer Treat Rev · review; journal article · DOI 10.1016/j.ctrv.2015.09.005Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM.
Expert Rev Anticancer Ther · comparative study; journal article · DOI 10.1586/14737140.2015.1088787Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID.
Lancet Oncol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(15)00034-0Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM.
Lancet Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(15)00035-2Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B, Chua D, Poma A, Arora S, Wang Y, Fein LE.
Support Care Cancer · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00520-015-2738-1Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Jordan K, Jahn F, Aapro M.
Ann Oncol · review; journal article · DOI 10.1093/annonc/mdv138New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS, Rugo HS, Aapro MS.
Clin Adv Hematol Oncol · research support, non-u.s. gov't; journal articleClinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
Morrow GR, Navari RM, Rugo HS.
Clin Adv Hematol Oncol · research support, non-u.s. gov't; journal articleRolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM.
Pharmacol Biochem Behav · journal article · DOI 10.1016/j.pbb.2012.03.021